High prevalence and significant ethnic differences in actionable HbA1C after gestational diabetes mellitus in women living in Norway

被引:5
作者
Sharma, Archana [1 ,2 ]
Nermoen, Ingrid [1 ,2 ]
Qvigstad, Elisabeth [2 ,3 ]
Tran, Anh T. [4 ]
Sommer, Christine [2 ,3 ]
Sattar, Naveed [5 ]
Gill, Jason M. R. [5 ]
Gulseth, Hanne L. [6 ]
Sollid, Stina T. [7 ]
Birkeland, Kare, I [2 ,3 ]
机构
[1] Univ Oslo, Akershus Univ Hosp, Dept Endocrinol, N-1478 Lorenskog, Norway
[2] Univ Oslo, Inst Clin Med, Oslo, Norway
[3] Oslo Univ Hosp, Dept Endocrinol Morbid Obes & Prevent Med, Oslo, Norway
[4] Univ Oslo, Inst Hlth & Soc, Dept Gen Practice, Oslo, Norway
[5] Univ Glasgow, BHF Glasgow Cardiovasc Res Ctr, Inst Cardiovasc & Med Sci, 126 Univ Pl, Glasgow G12 8TA, Lanark, Scotland
[6] Norwegian Inst Publ Hlth, Oslo, Norway
[7] Drammen Hosp, Dept Med, Vestre Viken Hlth Trust, Drammen, Norway
关键词
Gestational diabetes mellitus; Glucose metabolism disorders; Ethnic groups; Prevention; Overweight; Glycated haemoglobin; LIFE-STYLE INTERVENTION; GLUCOSE-TOLERANCE; CARDIOVASCULAR-DISEASE; NORBERT FREINKEL; PREGNANCY; CRITERIA; RISK; HYPERGLYCEMIA; PREVENTION; DIAGNOSIS;
D O I
10.1186/s12916-022-02515-w
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The type 2 diabetes risk after gestational diabetes mellitus (GDM) is twice as high in South Asian compared to European women. Current guidelines differ regarding which test to use as a screening-tool post-GDM. We aimed to identify ethnic differences in the prevalence rates and early predictors for actionable HbA(1c) (defined as prediabetes and diabetes) short time after GDM. Methods This cross-sectional study, enrolling South Asian and Nordic women 1-3 years after a diagnosis of GDM, was undertaken at three hospitals in Norway. We performed a clinical and laboratory evaluation including an oral glucose tolerance test (OGTT). Medical records were used to retrieve data during pregnancy. Prediabetes was classified with HbA(1c) alone or combined with OGTT glucose measurements according to the WHO, WHO-IEC, and ADA criteria (fasting plasma glucose (FPG) 6.1-6.9 mmol/L, FPG 6.1-6.9 mmol/L and/or HbA(1c) 42-47 mmol/mol (6.0-6.4%), and FPG 5.6-6.9 mmol/L and/or HbA(1c) 39-47 mmol/mol (5.7-6.4%)). Ethnic differences in prevalence and predictors of glucose deterioration were assed by chi(2) (Pearson) tests and logistic regression models. Results We included 163 South Asian and 108 Nordic women. Actionable HbA(1c) levels were highly prevalent and more so among South Asian than Nordic women (WHO-IEC-HbA(1c): 25.8% vs. 6.5% (p <= 0.001), ADA-HbA(1c): 58.3% vs. 22.2% (p <= 0.001)). Although adding OGTT-data gave higher combined prevalence rates of prediabetes and diabetes (WHO: 65.6% vs. 47.2% (p <= 0.05), WHO-IEC: 70.6% vs. 47.2% (p <= 0.001), ADA: 87.8% vs. 65.7% (p <= 0.001)), the excess risk in the South Asian women was best captured by the HbA(1c). Important predictors for glucose deterioration after GDM were: South Asian ethnicity, GDM before the index pregnancy, use of glucose-lowering drugs in pregnancy, higher age, and higher in-pregnancy fasting glucose levels. Conclusions In women with GDM 1-3 year previously, we found high prevalence and significant ethnic differences in actionable ADA-HbA(1c) levels, with South Asian ethnicity, GDM before the index pregnancy, and the use of glucose-lowering drugs in pregnancy as the most important risk factors. This study reinforces the importance of annual screening-preferably with HbA(1c) measurements-to facilitate early intervention after GDM.
引用
收藏
页数:10
相关论文
共 47 条
  • [1] Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO
  • [2] 2-S
  • [3] 14. Management of Diabetes in Pregnancy: Standards of Medical Care in Diabetes-2021
    不详
    [J]. DIABETES CARE, 2021, 44 : S200 - S210
  • [4] 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2022
    American Diabetes Association Professional Practice Committee
    [J]. DIABETES CARE, 2022, 45 : S17 - S38
  • [5] American Diabetes Association, 2022, Diabetes Care, V45, pS232, DOI DOI 10.2337/DC22-S015
  • [7] Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies
    Barba, C
    Cavalli-Sforza, T
    Cutter, J
    Darnton-Hill, I
    Deurenberg, P
    Deurenberg-Yap, M
    Gill, T
    James, P
    Ko, G
    Miu, AH
    Kosulwat, V
    Kumanyika, S
    Kurpad, A
    Mascie-Taylor, N
    Moon, HK
    Nishida, C
    Noor, MI
    Reddy, KS
    Rush, E
    Schultz, JT
    Seidell, J
    Stevens, J
    Swinburn, B
    Tan, K
    Weisell, R
    Wu, ZS
    Yajnik, CS
    Yoshiike, N
    Zimmet, P
    [J]. LANCET, 2004, 363 (9403) : 157 - 163
  • [8] Metabolic Culprits in Obese Pregnancies and Gestational Diabetes Mellitus: Big Babies, Big Twists, Big Picture The 2018 Norbert Freinkel Award Lecture
    Barbour, Linda A.
    [J]. DIABETES CARE, 2019, 42 (05) : 718 - 726
  • [9] Prediction of Glucose Intolerance in Early Postpartum in Women with Gestational Diabetes Mellitus Based on the 2013 WHO Criteria
    Benhalima, Katrien
    Van Crombrugge, Paul
    Moyson, Carolien
    Verhaeghe, Johan
    Vandeginste, Sofie
    Verlaenen, Hilde
    Vercammen, Chris
    Maes, Toon
    Dufraimont, Els
    De Block, Christophe
    Jacquemyn, Yves
    Mekahli, Farah
    De Clippel, Katrien
    Van Den Bruel, Annick
    Loccufier, Anne
    Laenen, Annouschka
    Minschart, Caro
    Devlieger, Roland
    Mathieu, Chantal
    [J]. JOURNAL OF CLINICAL MEDICINE, 2019, 8 (03)
  • [10] Glucose tolerance and cardiovascular mortality -: Comparison of fasting and 2-hour diagnostic criteria
    Borch-Johnsen, K
    Neil, A
    Balkau, B
    Larsen, S
    Nissinen, A
    Pekkanen, J
    Tuomilehto, J
    Jousilahti, P
    Lindstrom, J
    Pyörälä, M
    Pyörälä, K
    Eschwege, E
    Gallus, G
    Garancini, MP
    Bouter, LM
    Dekker, JM
    Heine, RJ
    Nijpels, HG
    Stehouwer, CDA
    Feskens, EJM
    Kromhout, D
    Peltonen, M
    Pajak, A
    Eriksson, J
    Qiao, Q
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2001, 161 (03) : 397 - 405